Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors

NCT01734564 Phase 2 COMPLETED

In this phase II study, patients with solid tumors will receive treatment with hiltonol and autologous dendritic cells.

Details

Lead sponsor	Clinica Universidad de Navarra, Universidad de Navarra
Phase	Phase 2
Status	COMPLETED
Enrolment	15
Start date	2012-11
Completion	2016-12

Conditions

• Neoplasms

Interventions

• Hiltonol and autologous dendritic cells
• Hiltonol, dendritic cells and radiation

Primary outcomes

• Response rate — 8-10 weeks

Countries

Spain